NextCure (NASDAQ:NXTC) Issues Quarterly Earnings Results, Misses Estimates By $0.85 EPS

NextCure (NASDAQ:NXTC) posted its quarterly earnings results on Thursday. The company reported ($2.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.95) by ($0.85), FiscalAI reports.

NextCure Price Performance

NextCure stock traded up $0.25 during mid-day trading on Friday, reaching $5.84. The company had a trading volume of 290,316 shares, compared to its average volume of 6,419,686. The stock’s 50-day simple moving average is $3.35 and its 200-day simple moving average is $8.41. NextCure has a 1 year low of $1.55 and a 1 year high of $15.74. The company has a market capitalization of $21.08 million, a P/E ratio of -0.67 and a beta of 1.27.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on NXTC shares. HC Wainwright reiterated a “buy” rating and set a $20.00 target price on shares of NextCure in a research report on Wednesday, July 15th. Weiss Ratings cut NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 7th. Wall Street Zen downgraded NextCure from a “hold” rating to a “sell” rating in a research note on Saturday, July 18th. Finally, Zacks Research raised NextCure from a “strong sell” rating to a “hold” rating in a report on Thursday, June 11th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, NextCure has a consensus rating of “Hold” and an average target price of $19.00.

Insider Activity at NextCure

In other news, major shareholder Adar1 Capital Management, Llc purchased 36,303 shares of the firm’s stock in a transaction dated Friday, July 31st. The shares were acquired at an average price of $4.94 per share, with a total value of $179,336.82. Following the purchase, the insider directly owned 722,419 shares of the company’s stock, valued at $3,568,749.86. The trade was a 5.29% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this link. Over the last 90 days, insiders purchased 346,761 shares of company stock worth $1,710,807. 11.90% of the stock is owned by insiders.

Hedge Funds Weigh In On NextCure

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Ikarian Capital LLC acquired a new stake in NextCure in the fourth quarter valued at $3,382,000. Squadron Capital Management LLC purchased a new position in shares of NextCure in the fourth quarter valued at $3,363,000. Affinity Asset Advisors LLC raised its stake in shares of NextCure by 28.9% during the 4th quarter. Affinity Asset Advisors LLC now owns 247,294 shares of the company’s stock worth $3,509,000 after buying an additional 55,412 shares during the last quarter. AWM Investment Company Inc. acquired a new position in shares of NextCure during the 4th quarter worth $1,665,000. Finally, Exome Asset Management LLC purchased a new stake in shares of NextCure in the 4th quarter worth about $2,341,000. 42.65% of the stock is owned by institutional investors and hedge funds.

NextCure Company Profile

NextCure, Inc is a clinical?stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large?scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.